hydroxyindoleacetic acid has been researched along with Basal Ganglia Diseases in 15 studies
(5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The introduction of the atypical neuroleptic, clozapine, has had widespread influence not only on the treatment of the seriously mentally ill patient, but also on new drug development and on hypotheses of the pathophysiology of schizophrenia." | 9.07 | Predictors of clozapine response in schizophrenia. ( Hsiao, JK; Litman, RE; Owen, RR; Pickar, D; Su, TP, 1994) |
| "The introduction of the atypical neuroleptic, clozapine, has had widespread influence not only on the treatment of the seriously mentally ill patient, but also on new drug development and on hypotheses of the pathophysiology of schizophrenia." | 5.07 | Predictors of clozapine response in schizophrenia. ( Hsiao, JK; Litman, RE; Owen, RR; Pickar, D; Su, TP, 1994) |
| " The results support the hypothesis of a positive correlation between the CSF HVA and the hypokinetic-rigid side effect and a negative correlation between the pretherapeutic dopamine turnover and the risk of neuroleptic Parkinsonism." | 1.27 | Hypokinetic-rigid extrapyramidal side effects of neuroleptics: the relationship of the silent period in EMG and HVA and 5-HIAA in CSF. ( Baslo, A; Eroğlu, L; Hizal, A; Yazici, J; Yazici, O, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (73.33) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saijoh, K | 1 |
| Katsuyama, H | 1 |
| Cramer, H | 1 |
| Warter, JM | 1 |
| Renaud, B | 1 |
| Tollefson, GD | 1 |
| Garvey, MJ | 1 |
| Pickar, D | 1 |
| Owen, RR | 1 |
| Litman, RE | 1 |
| Hsiao, JK | 1 |
| Su, TP | 1 |
| Haley, RW | 1 |
| Fleckenstein, JL | 1 |
| Marshall, WW | 1 |
| McDonald, GG | 1 |
| Kramer, GL | 1 |
| Petty, F | 1 |
| Van Praag, HM | 1 |
| Korf, J | 1 |
| Gerlach, J | 1 |
| Thorsen, K | 1 |
| Fog, R | 1 |
| Komatsu, H | 1 |
| Nishimura, A | 1 |
| Okano, S | 1 |
| Miyanomae, Y | 1 |
| Takeuchi, Y | 1 |
| Sawada, T | 1 |
| Kish, SJ | 1 |
| Chang, LJ | 1 |
| Mirchandani, L | 1 |
| Shannak, K | 1 |
| Hornykiewicz, O | 1 |
| Parenti, M | 1 |
| Flauto, C | 1 |
| Parati, E | 1 |
| Vescovi, A | 1 |
| Groppetti, A | 1 |
| Yazici, O | 1 |
| Hizal, A | 1 |
| Eroğlu, L | 1 |
| Baslo, A | 1 |
| Yazici, J | 1 |
| Sheng, JG | 1 |
| Xu, DL | 1 |
| Yu, HZ | 1 |
| Xu, XR | 1 |
| Tang, QM | 1 |
| Papeschi, R | 1 |
| Molina-Negro, P | 1 |
| Sourkes, TL | 1 |
| Erba, G | 1 |
| Chase, TN | 1 |
| Eben, E | 1 |
| Ackenheil, M | 1 |
| Raese, J | 1 |
| Rüther, E | 1 |
2 trials available for hydroxyindoleacetic acid and Basal Ganglia Diseases
| Article | Year |
|---|---|
Predictors of clozapine response in schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Double-Blind Method; Female; Fluphen | 1994 |
Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients.
Topics: Adult; Aged; Basal Ganglia Diseases; Clinical Trials as Topic; Clozapine; Dibenzazepines; Haloperido | 1975 |
13 other studies available for hydroxyindoleacetic acid and Basal Ganglia Diseases
| Article | Year |
|---|---|
[5-Hyroxyindol acetic acid (5HIAA)].
Topics: Adult; Basal Ganglia Diseases; Carcinoid Tumor; Chromatography, High Pressure Liquid; Gas Chromatogr | 2010 |
Analysis of neurotransmitter metabolites and adenosine 3',5'-monophosphate in the CSF of patients with extrapyramidal motor disorders.
Topics: Adult; Basal Ganglia Diseases; Cyclic AMP; Female; Homovanillic Acid; Humans; Huntington Disease; Hy | 1984 |
The neuroleptic syndrome and central dopamine metabolites.
Topics: 3,4-Dihydroxyphenylacetic Acid; Antipsychotic Agents; Basal Ganglia Diseases; Dopamine; Female; Homo | 1984 |
Effect of basal ganglia injury on central dopamine activity in Gulf War syndrome: correlation of proton magnetic resonance spectroscopy and plasma homovanillic acid levels.
Topics: Basal Ganglia Diseases; Brain; Chromatography, High Pressure Liquid; Diagnosis, Differential; Dopami | 2000 |
Importance of dopamine metabolism for clinical effects and side effects of neuroleptics.
Topics: Adult; Aged; Antiparkinson Agents; Basal Ganglia Diseases; Chlorpromazine; Dopamine; Dopamine Antago | 1976 |
Neuroleptic malignant syndrome-like state in a patient with Down syndrome and basal ganglia calcification.
Topics: Adolescent; Basal Ganglia Diseases; Calcinosis; Down Syndrome; Homovanillic Acid; Humans; Hydroxyind | 1992 |
Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers.
Topics: Aged; Aspartic Acid; Basal Ganglia Diseases; Brain; Bulbar Palsy, Progressive; Choline O-Acetyltrans | 1985 |
Manganese neurotoxicity: effects of L-DOPA and pargyline treatments.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Basal Ganglia Diseases; Corpus Striatum; Dopamine; Drug Syn | 1986 |
Hypokinetic-rigid extrapyramidal side effects of neuroleptics: the relationship of the silent period in EMG and HVA and 5-HIAA in CSF.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Electric Stimulation; Electromyography; Haloperidol; H | 1986 |
Partial protection from the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by Pro-Leu-Gly-NH2(PLG; MIF-1).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Basal Ganglia | 1987 |
The concentration of homovanillic and 5-hydroxyindoleacetic acids in ventricular and lumbar CSF. Studies in patients with extrapyramidal disorders, epilepsy, and other diseases.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Cerebral Palsy; Cerebral Ventricles; Diazepam; Dihydroxyp | 1972 |
Central monoamine metabolism in man. Effect of putative dopamine receptor agonists and antagonists.
Topics: Adult; Basal Ganglia Diseases; Brain; Central Nervous System Diseases; Dopamine; Haloperidol; Homova | 1973 |
[Biochemical mechanisms of extrapyramidal-motoric effect of haloperidol in man].
Topics: Adult; Basal Ganglia Diseases; Female; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic A | 1974 |